Last Update 09 Jun 26

GDRX: Pharma Direct Shift And New Offerings Will Support Future Upside

Analysts have lifted their GoodRx Holdings price targets by about $0.50 to $1, with recent moves to $4 from $3.50 at Citi and similar $1 increases at TD Cowen and Goldman Sachs. These changes reflect updated views on the stock's risk, growth, profitability and future P/E assumptions.

Analyst Commentary

Recent research updates around GoodRx cluster around the same broad price range, with analysts tweaking targets by about $0.50 to $1 and reassessing how the stock lines up with their risk, growth and profitability expectations.

Bullish Takeaways

Bullish analysts see room for the stock to better align with their longer term P/E assumptions, which supports the move toward a US$4 price target.
The cluster of higher targets suggests renewed confidence that GoodRx can execute on its business model well enough to justify slightly richer valuation multiples.
Supportive views point to the company’s ability to convert its existing platform and user base into more stable revenue, which feeds into upgraded pricing models.
The incremental nature of the target raises signals that, in the eyes of bullish analysts, the risk and reward profile has tilted modestly more favorably than before.

Bearish Takeaways

Bearish analysts may view the small size of the target increases as a sign that upside appears limited relative to execution risks and competition in the space.
Some may question whether profitability can consistently support the higher P/E assumptions used in recent models, especially if growth is uneven.
The tight clustering of targets around US$4 can be read as caution on both valuation expansion and the pace of business improvement, not a call for aggressive re-rating.
Investors focused on downside risk might see the modest target changes as a reminder that the margin for error on execution, pricing power and user engagement could still be narrow.

What’s in the News

GoodRx raised full year 2026 revenue guidance to a range of US$765 million to US$785 million and highlighted a focus on sustaining growth and maintaining margins. (Source: Company guidance)
The company is offering self-pay pricing for Novo Nordisk’s Ozempic pill (oral semaglutide), with eligible type 2 diabetes patients able to access the medication starting at US$149 per month, scaling to US$199 and US$299 for higher doses. (Source: Company product announcement)
GoodRx added access to the new higher dose Wegovy HD 7.2 mg injection, with eligible self-pay patients able to purchase at US$399 per month, or US$798 for two months and US$1,197 for three months, alongside its GoodRx for Weight Loss subscription service. (Source: Company product announcement)
GoodRx was removed from the NASDAQ Internet Index, changing its presence in at least one benchmark followed by some investors. (Source: Index change notice)
The Audit and Risk Committee appointed KPMG LLP as GoodRx’s independent registered public accounting firm for the 2026 fiscal year and dismissed PricewaterhouseCoopers LLP. (Source: Company auditor change announcement)

Valuation Changes

Fair Value: Model fair value remains steady at about $3.18 per share, with no change between the prior and updated estimates.
Discount Rate: The discount rate has risen slightly from about 9.37% to about 9.41%, pointing to a modestly higher required return in the model.
Revenue Growth: The revenue growth assumption is effectively unchanged, holding near 4.77% in both the prior and updated figures.
Net Profit Margin: The profit margin input is also effectively flat, staying close to 7.04% in the updated work.
Future P/E: The future P/E assumption has risen slightly from about 20.41x to about 20.43x, indicating a very small change in the expected valuation multiple.

0 views

Key Takeaways

Expanding uninsured populations and rising drug prices are increasing demand for GoodRx's affordable prescription solutions and growing its user base.
New pharma partnerships, digital health integrations, and targeted subscription services are boosting higher-margin, recurring, and diversified revenue streams.
Reliance on third-party partners, regulatory shifts, new competitors, and evolving pharmacy models threaten GoodRx's revenue stability, user growth, pricing power, and market position.

Catalysts

About GoodRx Holdings

Offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States.What are the underlying business or industry changes driving this perspective?

Increased uninsured and underinsured populations due to recent cuts in Medicaid funding and rising health premiums are likely to drive more Americans to seek affordable prescription solutions, boosting GoodRx's addressable market and supporting growth in transaction revenues.
Accelerating adoption of digital health and telemedicine, along with heightened consumer price sensitivity in the face of drug price inflation, positions GoodRx's platform as an increasingly vital resource, expanding its user base and raising potential for recurring revenue through digital pharmacy integrations.
Substantial momentum in the company's pharma manufacturer solutions (32% YoY revenue growth, with management projecting 30%+ in 2025) reflects strong demand for direct-to-patient engagement, unlocking higher-margin revenue streams and providing meaningful upside to consolidated revenue and net margins.
Launch and planned expansion of condition-specific and pharmacy subscription offerings (e.g., ED, weight loss, hair loss) utilize GoodRx's large, engaged audience, increasing customer lifetime value and generating more predictable and diversified revenue streams.
Deeper integration with pharmacies (pharmacy counter initiatives, e-commerce, Community Link for independents) improves partnership durability and operational efficiency, leading to higher retention, reduced churn from external disruptions, and better margin stability over time.

GoodRx Holdings Earnings and Revenue Growth

GoodRx Holdings Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming GoodRx Holdings's revenue will grow by 4.8% annually over the next 3 years.
Analysts assume that profit margins will increase from 2.6% today to 7.0% in 3 years time.
Analysts expect earnings to reach $63.8 million (and earnings per share of $0.23) by about June 2029, up from $20.6 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $98.5 million in earnings, and the most bearish expecting $24.8 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 20.5x on those 2029 earnings, down from 43.3x today. This future PE is lower than the current PE for the US Healthcare Services industry at 28.9x.
Analysts expect the number of shares outstanding to decline by 2.53% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 9.41%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Structural changes in the pharmacy and PBM ecosystem, such as the Rite Aid bankruptcy and rapid network removals, have led to immediate and significant volume shocks for GoodRx, exposing its reliance on third-party partners and indicating ongoing risks to top-line revenue whenever major partners experience operational distress or make network changes.
Erosion in the Integrated Savings Program (ISP), particularly due to PBM partners restructuring or deprioritizing the program, demonstrates how GoodRx's ability to drive prescription transaction volumes is increasingly subject to decisions outside its control; this can result in direct revenue loss, increased choppiness in monthly active user counts, and future gross margin compression.
The pivot toward cost-plus and more bespoke pharmacy arrangements, while intended to improve retail partner economics, has led to higher prices at the point of sale, pressuring consumer demand for cash-pay scripts, which could further accelerate the shift of scripts back to funded benefits and constrain growth in GoodRx's core user base-ultimately impacting both revenue and net margins.
Intensifying competition in direct-to-consumer prescription models (e.g., Amazon Pharmacy, digital-first health platforms) and the prospect of vertical integration among PBMs, health plans, and retail pharmacies pose a disintermediation threat to GoodRx, as competitors may bypass or undercut its pricing tools, shrinking market share and reducing future top line expansion.
Regulatory changes increasing healthcare price transparency or implementing government-driven direct-to-consumer pricing models (e.g., Most Favored Nation pricing proposals) may "commoditize" GoodRx's offerings, eroding their pricing power and reducing their differentiation, which could shrink the addressable market and exert sustained pressure on revenues and margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $3.18 for GoodRx Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $4.0, and the most bearish reporting a price target of just $2.25.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $906.0 million, earnings will come to $63.8 million, and it would be trading on a PE ratio of 20.5x, assuming you use a discount rate of 9.4%.
Given the current share price of $2.63, the analyst price target of $3.18 is 17.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on GoodRx Holdings?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Digital Health And Telemedicine Expansion Will Deepen Market Opportunity